Literature DB >> 35999375

MRI features associated with HCC histologic subtypes: a western American and European bicenter study.

Sébastien Mulé1,2, Ali Serhal3, Athena Galletto Pregliasco4, Jessica Nguyen5, Camila Lopes Vendrami6, Edouard Reizine4, Guang-Yu Yang5, Julien Calderaro7,8, Giuliana Amaddeo7,9, Alain Luciani4,7, Frank H Miller6.   

Abstract

OBJECTIVES: To evaluate if preoperative MRI can predict the most frequent HCC subtypes in North American and European patients treated with surgical resection.
METHODS: A total of 119 HCCs in 97 patients were included in the North American group and 191 HCCs in 176 patients were included in the European group. Lesion subtyping was based on morphologic features and immuno-histopathological analysis. Two radiologists reviewed preoperative MRI and evaluated the presence of imaging features including LI-RADS major and ancillary features to identify clinical, biologic, and imaging features associated with the main HCC subtypes.
RESULTS: Sixty-four percent of HCCs were conventional. The most frequent subtypes were macrotrabecular-massive (MTM-15%) and steatohepatitic (13%). Necrosis (OR = 3.32; 95% CI: 1.39, 7.89; p = .0064) and observation size (OR = 1.011; 95% CI: 1.0022, 1.019; p = .014) were independent predictors of MTM-HCC. Fat in mass (OR = 15.07; 95% CI: 6.57, 34.57; p < .0001), tumor size (OR = 0.97; 95% CI: 0.96, 0.99; p = .0037), and absence of chronic HCV infection (OR = 0.24; 95% CI: 0.084, 0.67; p = .0068) were independent predictors of steatohepatitic HCC. Independent predictors of conventional HCCs were viral C hepatitis (OR = 3.20; 95% CI: 1.62, 6.34; p = .0008), absence of fat (OR = 0.25; 95% CI: 0.12, 0.52; p = .0002), absence of tumor in vein (OR = 0.34; 95% CI: 0.13, 0.84; p = .020), and higher tumor-to-liver ADC ratio (OR = 1.96; 95% CI: 1.14, 3.35; p = .014)
CONCLUSION: MRI is useful in predicting the most frequent HCC subtypes even in cohorts with different distributions of liver disease etiologies and tumor subtypes which might have future treatment and management implications. KEY POINTS: • Representation of both liver disease etiologies and HCC subtypes differed between the North American and European cohorts of patients. • Retrospective two-center study showed that liver MRI is useful in predicting the most frequent HCC subtypes.
© 2022. The Author(s), under exclusive licence to European Society of Radiology.

Entities:  

Keywords:  Hepatocellular carcinoma; Histology subtypes; Liver MRI

Year:  2022        PMID: 35999375     DOI: 10.1007/s00330-022-09085-8

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   7.034


  20 in total

1.  Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.

Authors:  Derek Y Chiang; Augusto Villanueva; Yujin Hoshida; Judit Peix; Philippa Newell; Beatriz Minguez; Amanda C LeBlanc; Diana J Donovan; Swan N Thung; Manel Solé; Victoria Tovar; Clara Alsinet; Alex H Ramos; Jordi Barretina; Sasan Roayaie; Myron Schwartz; Samuel Waxman; Jordi Bruix; Vincenzo Mazzaferro; Azra H Ligon; Vesna Najfeld; Scott L Friedman; William R Sellers; Matthew Meyerson; Josep M Llovet
Journal:  Cancer Res       Date:  2008-08-15       Impact factor: 12.701

2.  Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification.

Authors:  Julien Calderaro; Gabrielle Couchy; Sandrine Imbeaud; Giuliana Amaddeo; Eric Letouzé; Jean-Frédéric Blanc; Christophe Laurent; Yacine Hajji; Daniel Azoulay; Paulette Bioulac-Sage; Jean-Charles Nault; Jessica Zucman-Rossi
Journal:  J Hepatol       Date:  2017-05-19       Impact factor: 25.083

Review 3.  Genetic Landscape and Biomarkers of Hepatocellular Carcinoma.

Authors:  Jessica Zucman-Rossi; Augusto Villanueva; Jean-Charles Nault; Josep M Llovet
Journal:  Gastroenterology       Date:  2015-06-20       Impact factor: 22.682

4.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.

Authors:  Hyuna Sung; Jacques Ferlay; Rebecca L Siegel; Mathieu Laversanne; Isabelle Soerjomataram; Ahmedin Jemal; Freddie Bray
Journal:  CA Cancer J Clin       Date:  2021-02-04       Impact factor: 508.702

5.  Prognosis of hepatocellular carcinoma: the BCLC staging classification.

Authors:  J M Llovet; C Brú; J Bruix
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

Review 6.  BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update.

Authors:  Maria Reig; Alejandro Forner; Jordi Rimola; Joana Ferrer-Fàbrega; Marta Burrel; Ángeles Garcia-Criado; Robin K Kelley; Peter R Galle; Vincenzo Mazzaferro; Riad Salem; Bruno Sangro; Amit G Singal; Arndt Vogel; Josep Fuster; Carmen Ayuso; Jordi Bruix
Journal:  J Hepatol       Date:  2021-11-19       Impact factor: 30.083

Review 7.  Comparison of hepatocellular carcinoma in Eastern versus Western populations.

Authors:  Su Pin Choo; Wan Ling Tan; Brian K P Goh; Wai Meng Tai; Andrew X Zhu
Journal:  Cancer       Date:  2016-09-13       Impact factor: 6.860

8.  International trends in hepatocellular carcinoma incidence, 1978-2012.

Authors:  Jessica L Petrick; Andrea A Florio; Ariana Znaor; David Ruggieri; Mathieu Laversanne; Christian S Alvarez; Jacques Ferlay; Patricia C Valery; Freddie Bray; Katherine A McGlynn
Journal:  Int J Cancer       Date:  2019-11-05       Impact factor: 7.316

Review 9.  Update on hepatocellular carcinoma: Pathologists' review.

Authors:  Tony El Jabbour; Stephen M Lagana; Hwajeong Lee
Journal:  World J Gastroenterol       Date:  2019-04-14       Impact factor: 5.742

10.  Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma.

Authors:  Yujin Hoshida; Sebastian M B Nijman; Masahiro Kobayashi; Jennifer A Chan; Jean-Philippe Brunet; Derek Y Chiang; Augusto Villanueva; Philippa Newell; Kenji Ikeda; Masaji Hashimoto; Goro Watanabe; Stacey Gabriel; Scott L Friedman; Hiromitsu Kumada; Josep M Llovet; Todd R Golub
Journal:  Cancer Res       Date:  2009-09-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.